Roche (SWX: RO), a major Swiss pharmaceutical company, has renewed its 46-year partnership with Japan’s Hitachi High-Tech (TYO: 6501) for an additional 10 years to develop innovative diagnostic solutions. This long-standing collaboration has led to an annual impact of over 21 billion in-vitro diagnostic tests, facilitated by more than 84,000 installed units across the globe. The two companies plan to introduce two new analytical platforms to the market by the end of this year.- Flcube.com
Recent news:
-
Sino Biopharmaceutical Submits NDA for Anlotinib and Penpulimab Combo in HCC to NMPA -
Sihuan Pharmaceutical's Huisheng Pharm Strikes Exclusive Deal for Semaglutide Biosimilar in China -
Innovent Biologics' IBI354 Earns Breakthrough Therapy Designation for Ovarian Cancer Treatment -
CDE Includes Double-Crane's Hydroxocobalamine and Sanofi Genzyme's Fitusiran in Rare Disease Care Plan -
Apeiron Therapeutics Initiates Phase Ia/B Study for GTA182 in Solid Tumors with MTAP Deficiency
